ClinicalTrials.gg
CompletedNCT02940886Updated Oct 6, 2020Results posted

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

A Phase 3 interventional study of Iron isomaltoside/ferric derisomaltose and Iron sucrose in Iron Deficiency Anaemia and Iron Deficiency Anemia, sponsored by Pharmacosmos A/S. Completed at 114 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-06.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,512
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Enrollment
3rd of 32
1,512 · median 121
Started
2016
with 3 others
Phase 3
18 of 32
4 open now
Registered
8th of 32
by date
Lead sponsor
13 of 32
Pharmacosmos A/S

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 3rd largest by enrollment, is one of 4 that started in 2016, is one of 18 in phase 3, and was the 8th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

Evaluate safety and efficacy of iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®) compared with iron sucrose (Venofer®), in subjects diagnosed with IDA.

Read the detailed description

IDA is highly prevalent condition in subjects with cancer and gastrointestinal diseases such as inflammatory bowel diseases, menstruating or pregnant women, and subjects who have undergone bariatric procedure or surgery. IDA can have a substantial medical and quality of life (QoL) burden. Treatment of subjects diagnosed with IDA includes controlling the bleeding and replenishing lost iron.

This study was designed to evaluate the safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose in subjects diagnosed with IDA. In a subfraction of 35 subjects treated with iron isomaltoside/ferric derisomaltose, ECG and iron will be frequently measured.

The study subjects received either a single intravenous (IV) dose of iron isomaltoside/ferric derisomaltose (1000 mg at baseline) or iron sucrose (200 mg IV injections at baseline and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline; a cumulative dose of 1000 mg was recommended). The study subjects were monitored for up to 8 weeks from baseline.

03

Conditions studied

  • Iron Deficiency Anaemia
  • Iron Deficiency Anemia

Keywords

  • Iron Deficiency Anaemia
  • Iron Deficiency Anemia
  • IDA
  • Intravenous iron replacement therapy
  • Iron isomaltoside
  • Ferric derisomaltose
  • Monofer
  • Monoferric
  • Monover
  • Monofar
  • Monoferro
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women ≥ 18 years
  2. Subjects having IDA caused by different etiologies
  3. Subjects with intolerance to oral iron therapy or a need for rapid repletion of iron stores:
  4. (Hb) ≤ 11 g/dL
  5. Transferrin Saturation (TSAT) \< 20 %
  6. S-ferritin \< 100 ng/mL
  7. Willingness to participate and signing the form

Exclusion criteria

Exclusion Criteria includes :

  1. Anemia predominantly caused by factors other than IDA
  2. Hemochromatosis or other iron storage disorders
  3. Previous serious reactions to any IV iron compound
  4. Erythropoiesis stimulating agent (ESA) treatment
  5. Prior to screening or during the trial period; has or will be treated with a red blood cell transfusion, radiotherapy, and/or chemotherapy
  6. Will require a surgical procedure that necessitated general anesthesia prior to screening or during the trial period
  7. and/or aspartate aminotransferase > 3 times
  8. Required dialysis for treatment of chronic kidney disease (CKD)
  9. Alcohol or drug abuse within the past 6 months
  10. Pregnant or nursing women
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,512 participants (actual)

Study arms

  • Experimental
    Iron isomaltoside/ferric derisomaltose

    Administered IV

    Drug: Iron isomaltoside/ferric derisomaltose

  • Active comparator
    Iron sucrose

    Administered IV

    Drug: Iron sucrose

Interventions

  • DrugIron isomaltoside/ferric derisomaltose

    Drug page: Iron isomaltoside 1000

    Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial. The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes.

    Also known as: Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®

  • Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.

    Also known as: Venofer®

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin (Hb) From Baseline to Week 8

    Efficacy Evaluate the effect on the hemoglobin (Hb) level following treatment with iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with iron deficiency anaemia (IDA) . Response was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with IDA, when oral iron preparations were ineffective or could not be used or in whom the screening Hb measurement in Investigators' opinion were sufficiently low to require rapid repletion of iron stores.

    Time frame: Baseline to week 8

  2. Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions

    Safety For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity reactions that were included in the analysis were those that started on or after the first dose of randomised treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: loss of consciousness, seizure, syncope, unresponsiveness. The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.

    Time frame: Baseline to week 8

Secondary outcomes

  1. Composite Cardiovascular Adverse Events (AEs)

    Safety Results show the composite cardiovascular adverse events (AEs), that started on or after the first dose of randomised treatment (i.e. treatment emergent) up to week 8. The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). The potential cardiovascular AEs included the following: * Death due to any cause * Non-fatal myocardial infarction * Non-fatal stroke * Unstable angina requiring hospitalisation * Congestive heart failure requiring hospitalisation or medical intervention * Arrhythmias * Hypertension * Hypotension Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.

    Time frame: Baseline, week 1, 2, and 8

  2. Time to First Composite Cardiovascular Safety AE

    Safety Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the CEAC, were considered for this endpoint. Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.

    Time frame: Baseline, week 1, 2, 4, and 8

  3. S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8

    Safety Results show the number of subjects who had s-phosphate \<2 mg/dL at any time from baseline to week 1, 2, 4, or 8.

    Time frame: Baseline, week 1, 2, 4, and 8

  4. Hb Concentration Increase of ≥2 g/dL From Baseline to Week 1, 2, 4, and 8

    Efficacy Results show responders to the treatment. A subject was considered a Hb responder to a certain week if an increase in Hb of at least 2 g/dL from baseline to the week in question was observed (week 1, 2, 4, and 8).

    Time frame: Baseline, week 1, 2, 4, and 8

  5. Time to Change in Hb Concentration ≥2 g/dL

    Efficacy Time to change in Hb concentration ≥2 g/dL. Subjects who achieved Hb concentration increase of ≥2 g/dL (from baseline to week 1, 2, 4, or 8). For responders, time to Hb response was defined as the scheduled time from baseline until the visit where the first Hb response was measured.

    Time frame: Baseline, week 1, 2, 4, and 8

  6. Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8

    Efficacy Hb concentration of \>12 g/dL at any time from week 1 to week 8. Results show the number of participants who achieved Hb concentration of \>12 g/dL at any time from week 1 to week 8.

    Time frame: Week 1 to week 8

  7. Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8

    Efficacy Results show the number of participants who achieved Hb concentration increase of ≥2 g/dL at any time from week 1 to week 8.

    Time frame: Week 1 to week 8

  8. S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8

    Efficacy Proportion of subjects reaching the composite endpoint of s-ferritin concentration ≥100 ng/mL and TSAT of 20-50% at any time from week 1 to 8.

    Time frame: Week 1 to week 8

  9. Change in Hb Concentration From Baseline to Week 1, 2, and 4

    Efficacy Change in Hb concentration from baseline to week 1, 2, and 4.

    Time frame: Baseline, week 1, 2, and 4

  10. Change in S-ferritin Concentration From Baseline to Weeks 1, 2, 4, and 8

    Efficacy Change in s-ferritin concentration from baseline to weeks 1, 2, 4, and 8.

    Time frame: Baseline, week 1, 2, 4, and 8

  11. Change in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8

    Efficacy Changes in transferrin saturation (TSAT) from baseline to week 1, 2, 4, and 8. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.

    Time frame: Baseline, week 1, 2, 4, and 8

  12. Change in Concentrations of Serum Iron (S-iron) From Baseline to Week 1, 2, 4, and 8

    Efficacy Changes in the concentrations of serum iron (s-iron) from baseline to week 1, 2, 4, and 8.

    Time frame: Baseline, week 1, 2, 4, and 8

  13. Change in Fatigue Symptoms From Baseline to Week 1, 2, and 8

    Efficacy Change in fatigue symptoms from baseline to week 1, 2, and 8 was measured by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. The Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale consisted of 13 items ranging from 0 (not at all) to 4 (very much), except items #7 and #8 which are reversed scored. The total score range is 0-52. A score of less than 30 indicated severe fatigue, and the higher the score, the better outcome/quality of life (QoL). If more than 50% of the items for a subject at a given visit were missing, the total score was not calculated. Total score was calculated as shown below: Total score= Sum of individual scores x 13 / Number of items answered

    Time frame: Baseline, week 1, 2, and 8

  14. Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking

    Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

    Time frame: Baseline

  15. Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car

    Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

    Time frame: Baseline

  16. Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit

    Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

    Time frame: Baseline

  17. Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits

    Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

    Time frame: Baseline

  18. Health Care Resource Use Questionnaire

    Pharmacoeconomics Resources used by the health care staff (per administration), measured by the health care resource use questionnaire. The questionnaire assessed the time used by the health care staff during administration of the investigational product and the administration time (including the observational time). The health care participants included in the evaluation were: investigator, pharmacist, physician, study coordinator, study nurse. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the treatment groups is different (i.e. up to a factor 5 more frequent in the iron sucrose treatment group).

    Time frame: Baseline

07

Results

Posted Mar 10, 2020

Participant flow

A total of 3108 subjects were screened and 1512 subjects were randomised in the trial.

Participant flow — Overall Study
MilestoneIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Started1009503
Safety analysis set989494
Completed907449
Not completed10254
Withdrew: Adverse event73
Withdrew: Protocol violation02
Withdrew: Withdrawal by subject2820
Withdrew: Death10
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up4921
Withdrew: Physician decision94
Withdrew: Sponsor decision01
Withdrew: No treatment72
Withdrew: Enrolment error01

Outcome measures

PrimaryChange in Hemoglobin (Hb) From Baseline to Week 8

Efficacy Evaluate the effect on the hemoglobin (Hb) level following treatment with iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with iron deficiency anaemia (IDA) . Response was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with IDA, when oral iron preparations were ineffective or could not be used or in whom the screening Hb measurement in Investigators' opinion were sufficiently low to require rapid repletion of iron stores.

Time frame:
Baseline to week 8
Reported as:
Least squares mean · g/dL
Change in Hemoglobin (Hb) From Baseline to Week 8
g/dLIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Change in Hemoglobin (Hb) From Baseline to Week 82.49 (2.41 to 2.56)2.49 (2.38 to 2.59)
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mean difference (final values): 0.00 · 95% CI -0.13 to 0.13Mixed Model for Repeated Measurement was used for testing and included the fixed categorical effects of treatment, week, treatment-by-week interaction, strata, and the continuous covariates of baseline Hb and baseline Hb-by-week interaction.
PrimaryIncidence of Protocol-defined Serious or Severe Hypersensitivity Reactions

Safety For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity reactions that were included in the analysis were those that started on or after the first dose of randomised treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: loss of consciousness, seizure, syncope, unresponsiveness. The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.

Time frame:
Baseline to week 8
Reported as:
Count of participants · Participants
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions32
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose · 95% two-sided ci (iron isomaltoside): 0.3 · 95% CI 0.06 to 0.88
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Risk difference (rd): -0.10 · 95% CI -0.91 to 0.71
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Risk difference (rd): 0.10 · 95% CI -0.57 to 0.48
SecondaryComposite Cardiovascular Adverse Events (AEs)

Safety Results show the composite cardiovascular adverse events (AEs), that started on or after the first dose of randomised treatment (i.e. treatment emergent) up to week 8. The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). The potential cardiovascular AEs included the following: * Death due to any cause * Non-fatal myocardial infarction * Non-fatal stroke * Unstable angina requiring hospitalisation * Congestive heart failure requiring hospitalisation or medical intervention * Arrhythmias * Hypertension * Hypotension Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.

Time frame:
Baseline, week 1, 2, and 8
Reported as:
Count of participants · Participants
Composite Cardiovascular Adverse Events (AEs)
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Composite Cardiovascular Adverse Events (AEs)86
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Fisher Exact · p = 0.5695
SecondaryTime to First Composite Cardiovascular Safety AE

Safety Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the CEAC, were considered for this endpoint. Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Median · Week
Time to First Composite Cardiovascular Safety AE
WeekIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Time to First Composite Cardiovascular Safety AENA (NA to NA)NA (NA to NA)
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Log Rank · p = 0.3913
SecondaryS-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8

Safety Results show the number of subjects who had s-phosphate \<2 mg/dL at any time from baseline to week 1, 2, 4, or 8.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Count of participants · Participants
S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 83811
SecondaryHb Concentration Increase of ≥2 g/dL From Baseline to Week 1, 2, 4, and 8

Efficacy Results show responders to the treatment. A subject was considered a Hb responder to a certain week if an increase in Hb of at least 2 g/dL from baseline to the week in question was observed (week 1, 2, 4, and 8).

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Count of participants · Participants
Hb Concentration Increase of ≥2 g/dL From Baseline to Week 1, 2, 4, and 8
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Responder YES week 15112
Responder YES week 229794
Responder YES week 4514250
Responder YES week 8606309
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Repeated measures logistic regressioin · p = 0.0077 · Odds ratio (or): 2.44 · 95% CI 1.27 to 4.72
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Repeated measures logistic regressioin · p = <0.0001 · Odds ratio (or): 2.42 · 95% CI 1.80 to 3.26
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Repeated measures logistic regressioin · p = 0.1049 · Odds ratio (or): 1.23 · 95% CI 0.96 to 1.58
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Repeated measures logistic regressioin · p = 0.7032 · Odds ratio (or): 1.05 · 95% CI 0.80 to 1.38
SecondaryTime to Change in Hb Concentration ≥2 g/dL

Efficacy Time to change in Hb concentration ≥2 g/dL. Subjects who achieved Hb concentration increase of ≥2 g/dL (from baseline to week 1, 2, 4, or 8). For responders, time to Hb response was defined as the scheduled time from baseline until the visit where the first Hb response was measured.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Median · Days
Time to Change in Hb Concentration ≥2 g/dL
DaysIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Time to Change in Hb Concentration ≥2 g/dL28 (NA to NA)28 (28 to 56)
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Log Rank · p = 0.0880
SecondaryHb Concentration of >12 g/dL at Any Time From Week 1 to Week 8

Efficacy Hb concentration of \>12 g/dL at any time from week 1 to week 8. Results show the number of participants who achieved Hb concentration of \>12 g/dL at any time from week 1 to week 8.

Time frame:
Week 1 to week 8
Reported as:
Count of participants · Participants
Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8484225
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Regression, Logistic · p = 0.2420 · Odds ratio (or): 1.14 · 95% CI 0.92 to 1.41
SecondaryHb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8

Efficacy Results show the number of participants who achieved Hb concentration increase of ≥2 g/dL at any time from week 1 to week 8.

Time frame:
Week 1 to week 8
Reported as:
Count of participants · Participants
Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8687340
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Regression, Logistic · p = 0.8746 · Odds ratio (or): 1.02 · 95% CI 0.81 to 1.28
SecondaryS-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8

Efficacy Proportion of subjects reaching the composite endpoint of s-ferritin concentration ≥100 ng/mL and TSAT of 20-50% at any time from week 1 to 8.

Time frame:
Week 1 to week 8
Reported as:
Count of participants · Participants
S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8
ParticipantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8680164
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.52 · 95% CI 3.58 to 5.71
SecondaryChange in Hb Concentration From Baseline to Week 1, 2, and 4

Efficacy Change in Hb concentration from baseline to week 1, 2, and 4.

Time frame:
Baseline, week 1, 2, and 4
Reported as:
Mean · g/dL
Change in Hb Concentration From Baseline to Week 1, 2, and 4
g/dLIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Week 10.70 ± 0.850.47 ± 0.69
Week 21.49 ± 1.131.25 ± 0.93
Week 42.15 ± 1.272.13 ± 1.10
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 0.26 · 95% CI 0.19 to 0.34
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 0.29 · 95% CI 0.19 to 0.38
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.1091 · Mean difference (final values): 0.09 · 95% CI -0.02 to 0.20
SecondaryChange in S-ferritin Concentration From Baseline to Weeks 1, 2, 4, and 8

Efficacy Change in s-ferritin concentration from baseline to weeks 1, 2, 4, and 8.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Mean · ng/mL
Change in S-ferritin Concentration From Baseline to Weeks 1, 2, 4, and 8
ng/mLIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Week 1373.5 ± 228.9105.7 ± 79.1
Week 2211.8 ± 152.4169.9 ± 129.8
Week 498.0 ± 103.9109.2 ± 108.7
Week 849.0 ± 79.758.7 ± 104.8
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 267.7 · 95% CI 246.3 to 289.0
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 41.7 · 95% CI 25.6 to 57.8
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.1150 · Mean difference (final values): -9.0 · 95% CI -20.3 to 2.2
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.0812 · Mean difference (final values): -8.3 · 95% CI -17.7 to 1.0
SecondaryChange in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8

Efficacy Changes in transferrin saturation (TSAT) from baseline to week 1, 2, 4, and 8. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Mean · percentage of saturation
Change in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8
percentage of saturationIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Week 116.68 ± 15.665.84 ± 10.52
Week 212.33 ± 13.4610.58 ± 12.67
Week 411.63 ± 12.0911.08 ± 8.59
Week 89.01 ± 12.588.87 ± 9.03
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 11.4 · 95% CI 10.1 to 12.7
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.0001 · Mean difference (final values): 2.4 · 95% CI 1.2 to 3.6
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.0162 · Mean difference (final values): 1.2 · 95% CI 0.2 to 2.1
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.0569 · Mean difference (final values): 0.9 · 95% CI 0.0 to 1.8
SecondaryChange in Concentrations of Serum Iron (S-iron) From Baseline to Week 1, 2, 4, and 8

Efficacy Changes in the concentrations of serum iron (s-iron) from baseline to week 1, 2, 4, and 8.

Time frame:
Baseline, week 1, 2, 4, and 8
Reported as:
Mean · μg/dL
Change in Concentrations of Serum Iron (S-iron) From Baseline to Week 1, 2, 4, and 8
μg/dLIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Week 163.2 ± 69.722.4 ± 44.4
Week 238.8 ± 58.137.0 ± 51.6
Week 431.2 ± 49.735.1 ± 33.2
Week 824.2 ± 53.327.6 ± 32.7
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 43.7 · 95% CI 38.1 to 49.3
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.0375 · Mean difference (final values): 5.0 · 95% CI 0.3 to 9.8
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.6027 · Mean difference (final values): -0.8 · 95% CI -4.0 to 2.3
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.8207 · Mean difference (final values): 0.4 · 95% CI -2.7 to 3.4
SecondaryChange in Fatigue Symptoms From Baseline to Week 1, 2, and 8

Efficacy Change in fatigue symptoms from baseline to week 1, 2, and 8 was measured by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. The Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale consisted of 13 items ranging from 0 (not at all) to 4 (very much), except items #7 and #8 which are reversed scored. The total score range is 0-52. A score of less than 30 indicated severe fatigue, and the higher the score, the better outcome/quality of life (QoL). If more than 50% of the items for a subject at a given visit were missing, the total score was not calculated. Total score was calculated as shown below: Total score= Sum of individual scores x 13 / Number of items answered

Time frame:
Baseline, week 1, 2, and 8
Reported as:
Mean · score on a scale
Change in Fatigue Symptoms From Baseline to Week 1, 2, and 8
score on a scaleIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Week 17.98 ± 10.417.38 ± 9.38
Week 210.74 ± 11.5811.89 ± 11.35
Week 814.08 ± 12.7015.36 ± 12.87
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.0422 · Mean difference (final values): 1.02 · 95% CI 0.04 to 2.01
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.4646 · Mean difference (final values): -0.39 · 95% CI -1.44 to 0.66
  • Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose · Mixed model for repeated measures · p = 0.5703 · Mean difference (final values): -0.31 · 95% CI -1.39 to 0.76
SecondaryIntervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking

Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

Time frame:
Baseline
Reported as:
Median · US dollars ($)
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking
US dollars ($)Iron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Cost of public transport/taxi5.0 (0 to 52)5.0 (0 to 100)
Cost of parking0.0 (0 to 30)0.0 (0 to 26)
SecondaryIntervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car

Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

Time frame:
Baseline
Reported as:
Median · miles
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car
milesIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car15.0 (0 to 200)15.0 (0 to 120)
SecondaryIntervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit

Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

Time frame:
Baseline
Reported as:
Median · Hours
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit
HoursIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Time spent on visit2.0 (0.0 to 20.0)2.0 (0.2 to 6.8)
Total time spent helping on visit2.0 (0.0 to 8.0)2.0 (0.0 to 6.0)
SecondaryIntervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits

Pharmacoeconomics The Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).

Time frame:
Baseline
Reported as:
Number · participants
Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits
participantsIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
In employment, YES529258
Took time off work to attend, YES233113
Assistance by others to attend visit, YES211111
Others took time off work to attend, YES6432
SecondaryHealth Care Resource Use Questionnaire

Pharmacoeconomics Resources used by the health care staff (per administration), measured by the health care resource use questionnaire. The questionnaire assessed the time used by the health care staff during administration of the investigational product and the administration time (including the observational time). The health care participants included in the evaluation were: investigator, pharmacist, physician, study coordinator, study nurse. The data for this endpoint show the responses at baseline for both treatment groups. The frequency of drug administration between the treatment groups is different (i.e. up to a factor 5 more frequent in the iron sucrose treatment group).

Time frame:
Baseline
Reported as:
Median · hours
Health Care Resource Use Questionnaire
hoursIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
Time spent per site staff median1.08 (0.0 to 8.0)1.00 (0.0 to 5.5)
Time spent per subject median3.38 (0.0 to 13.5)3.00 (0.0 to 15.8)

Adverse events

Collected over From the time a subjects had signed the informed consent form (CRF) and until they had completed the study, all adverse events (AEs) or serious adverse events (SAEs) were reported in the CRF. The actual study duration was 8 weeks (or shorted if the trial was discontinued). Overall, eligible subjects participated in the trial for approximately 10-15 weeks (including a 14-day screening period and if necessary a run-in period).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Iron Isomaltoside/Ferric Derisomaltose1/989 (0.1%)21/989 (2.1%)31/989 (3.1%)
Iron Sucrose0/494 (0%)13/494 (2.6%)16/494 (3.2%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
SyncopeNervous system disorders1/9892/494
Anaphylactic reactionImmune system disorders0/9892/494
Pancreatitis acuteGastrointestinal disorders0/9891/494
Peptic ulcerGastrointestinal disorders0/9891/494
Urinary tract infectionInfections and infestations2/9891/494
PyelonephritisInfections and infestations0/9891/494
HeadacheNervous system disorders0/9891/494
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/9891/494
Haemoglobin decreasedInvestigations0/9891/494
AnaemiaBlood and lymphatic system disorders1/9891/494
Most frequent other events
Most frequent other events
EventIron Isomaltoside/Ferric DerisomaltoseIron Sucrose
NauseaGastrointestinal disorders31/98916/494

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
<=18 years000
Between 18 and 65 years9024401342
>=65 years10763170
Age, Continuous
Age, Continuous(years)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
Mean44.1 ± 14.843.8 ± 14.444.0 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
Female8924561348
Male11747164
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
Hispanic or Latino387205592
Not Hispanic or Latino622298920
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
American Indian or Alaska Native415
Asian8412
Native Hawaiian or Other Pacific Islander123
Black or African American484223707
White504264768
More than one race303
Unknown or Not Reported5914
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
Arabic022
Hispanic336
Mix race (Black & White)303
Caucasian011
Haitian011
Latino101
Other (not declared)123
Region of Enrollment
Region of Enrollment(participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
United States10095031512
Current smoker
Current smoker(Participants)Iron Isomaltoside/Ferric DerisomaltoseIron SucroseTotal
YES13380213
NO8764231299
08

Study locations

114 sites
  • Pharmacosmos Investigational Site
    Birmingham, Alabama 35205, United States
  • Pharmacosmos Investigational Site
    Dothan, Alabama 36305, United States
  • Pharmacosmos Investigational Site
    Guntersville, Alabama 35976, United States
  • Pharmacosmos Investigational Site
    Phoenix, Arizona 85018, United States
  • Pharmacosmos Investigational Site
    Little Rock, Arkansas 72204, United States
  • Pharmacosmos Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pharmacosmos Investigational Site
    Foothill Ranch, California 92610, United States
  • Pharmacosmos Investigational Site 1
    La Mesa, California 91942, United States
  • Pharmacosmos Investigational Site 2
    La Mesa, California 91942, United States
  • Pharmacosmos Investigational Site
    Long Beach, California 90806, United States
  • Pharmacosmos Investigational Site
    National City, California 91950, United States
  • Pharmacosmos Investigational Site 1
    Northridge, California 91324, United States
  • Pharmacosmos Investigational Site 2
    Northridge, California 91324, United States
  • Pharmacosmos Investigational Site
    Oceanside, California 92056, United States
  • Pharmacosmos Investigational Site
    Quartz Hill, California 93536, United States
  • Pharmacosmos Investigational Site
    Rialto, California 92377, United States
  • Pharmacosmos Investigational Site
    Riverside, California 92501, United States
  • Pharmacosmos Investigational Site
    San Diego, California 92103, United States
  • Pharmacosmos Investigational Site
    San Diego, California 92117, United States
  • Pharmacosmos Investigational Site
    San Marcos, California 92078, United States
  • Pharmacosmos Investigational Site
    Whittier, California 90603, United States
  • Pharmacosmos Investigational Site
    Plainville, Connecticut 06062, United States
  • Pharmacosmos Investigational Site
    Aventura, Florida 33180, United States
  • Pharmacosmos Investigational Site
    Boynton Beach, Florida 33426, United States
  • Pharmacosmos Investigational Site 1
    Doral, Florida 33166, United States
  • Pharmacosmos Investigational Site 2
    Doral, Florida 33166, United States
  • Pharmacosmos Investigational Site
    Doral, Florida 33172, United States
  • Pharmacosmos Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • Pharmacosmos Investigational Site
    Hialeah, Florida 33012, United States
  • Pharmacosmos Investigational Site
    Hialeah, Florida 33015, United States
  • Pharmacosmos Investigational Site
    Hialeah, Florida 33016, United States
  • Pharmacosmos Investigational Site
    Hollywood, Florida 33024, United States
  • Pharmacosmos Investigational Site
    Jacksonville, Florida 32204, United States
  • Pharmacosmos Investigational Site
    Kissimmee, Florida 34741, United States
  • Pharmacosmos Investigational Site
    Lake City, Florida 32024, United States
  • Pharmacosmos Investigational Site
    Lake Worth, Florida 33461, United States
  • Pharmacosmos Investigational Site
    Lake Worth, Florida 33467, United States
  • Pharmacosmos Investigational Site 1
    Miami Lakes, Florida 33014, United States
  • Pharmacosmos Investigational Site 2
    Miami Lakes, Florida 33014, United States
  • Pharmacosmos Investigational Site
    Miami Lakes, Florida 33014, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33015, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33126, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33130, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33135, United States
  • Pharmacosmos Investigational Site 1
    Miami, Florida 33144, United States
  • Pharmacosmos Investigational Site 2
    Miami, Florida 33144, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33147, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33155, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33165, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33173, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33174, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33185, United States
  • Pharmacosmos Investigational Site 1
    Naples, Florida 34102, United States
  • Pharmacosmos Investigational Site 2
    Naples, Florida 34102, United States
  • Pharmacosmos Investigational Site
    Palmetto Bay, Florida 33157, United States
  • Pharmacosmos Investigational Site
    Plantation, Florida 33324, United States
  • Pharmacosmos Investigational Site
    West Palm Beach, Florida 33409, United States
  • Pharmacosmos Investigational Site
    Champaign, Illinois 61820, United States
  • Pharmacosmos Investigational Site
    Joliet, Illinois 60435, United States
  • Pharmacosmos Investigational Site
    Palos Heights, Illinois 60463, United States
  • Pharmacosmos Investigational Site
    Terre Haute, Indiana 47802, United States
  • Pharmacosmos Investigational Site
    Wichita, Kansas 67214, United States
  • Pharmacosmos Investigational Site
    Owensboro, Kentucky 42303, United States
  • Pharmacosmos Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • Pharmacosmos Investigational Site
    Marrero, Louisiana 70072, United States
  • Pharmacosmos Investigational Site
    Metairie, Louisiana 70006, United States
  • Pharmacosmos Investigational Site
    New Orleans, Louisiana 70125, United States
  • Pharmacosmos Investigational Site
    Shreveport, Louisiana 71103, United States
  • Pharmacosmos Investigational Site
    Bethesda, Maryland 20817, United States
  • Pharmacosmos Investigational Site
    Hagerstown, Maryland 21740, United States
  • Pharmacosmos Investigational Site
    Towson, Maryland 21204, United States
  • Pharmacosmos Investigational Site
    Fall River, Massachusetts 02720, United States
  • Pharmacosmos Investigational Site
    Grand Rapids, Michigan 49525, United States
  • Pharmacosmos Investigational Site
    Saginaw, Michigan 48604, United States
  • Pharmacosmos Investigational Site
    Troy, Michigan 48085, United States
  • Pharmacosmos Investigational Site
    Florissant, Missouri 63031, United States
  • Pharmacosmos Investigational Site
    Omaha, Nebraska 68134, United States
  • Pharmacosmos Investigational Site
    Las Vegas, Nevada 89109, United States
  • Pharmacosmos Investigational Site
    Neptune, New Jersey 07753, United States
  • Pharmacosmos Investigational Site
    Plainsboro, New Jersey 08536, United States
  • Brooklyn, New York 11235, United States
  • Pharmacosmos Investigational Site 1
    East Setauket, New York 11733, United States
  • Pharmacosmos Investigational Site 2
    East Setauket, New York 11733, United States
  • Pharmacosmos Investigational Site
    New York, New York 10016, United States
  • Pharmacosmos Investigational Site
    Wilmington, North Carolina 28401, United States
  • Pharmacosmos Investigational Site
    Wilmington, North Carolina 28403, United States
  • Pharmacosmos Investigational Site
    Beavercreek, Ohio 45431, United States
  • Pharmacosmos Investigational Site
    Canton, Ohio 44718, United States
  • Pharmacosmos Investigational Site
    Centerville, Ohio 45459, United States
  • Pharmacosmos Investigational Site
    Cincinnati, Ohio 45206, United States
  • Pharmacosmos Investigational Site
    Columbus, Ohio 43231, United States
  • Pharmacosmos Investigational Site
    Norman, Oklahoma 73069, United States
  • Pharmacosmos Investigational Site
    Tulsa, Oklahoma 74136, United States
  • Pharmacosmos Investigational Site
    Jenkintown, Pennsylvania 19046, United States
  • Pharmacosmos Investigational Site
    Columbia, South Carolina 29209, United States
  • Pharmacosmos Investigational Site
    Myrtle Beach, South Carolina 29572, United States
  • Pharmacosmos Investigational Site
    Chattanooga, Tennessee 37404, United States
  • Pharmacosmos Investigational Site
    Franklin, Tennessee 37067, United States
  • Pharmacosmos Investigational Site
    Knoxville, Tennessee 37923, United States
  • Pharmacosmos Investigational Site
    Memphis, Tennessee 38104, United States

Showing the first 100 of 114 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019 Sep;94(9):1007-1014. doi: 10.1002/ajh.25564. Epub 2019 Jul 13. PubMed 31243803 ↗
  • Auerbach M and Lykke LL. A single infusion of iron isomaltoside 1000 allows a more rapid hemoglobin increment than multiple doses of iron sucrose with a similar safety profile in patients with iron deficiency anemia. Blood 2018 132:2334; doi: https://doi.org/10.1182/blood-2018-99-110199

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2018, 16 months.

Results were first posted in Mar 2020, 1 year 11 months after primary completion. A results delay was requested in Mar 2019.

Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2016
First posted
Oct 21, 2016
StartActual
Nov 8, 2016
Primary completionActual
Mar 28, 2018
CompletionActual
Mar 28, 2018
Results delay requested
Mar 8, 2019
Results first posted
Mar 10, 2020
Last update
Oct 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02940886
Lead sponsor
Pharmacosmos A/S
Responsible party
Sponsor
First posted
Oct 21, 2016
Start date
Nov 8, 2016
Primary completion
Mar 28, 2018
Completion
Mar 28, 2018
Results posted
Mar 10, 2020
Last update
Oct 6, 2020

Study contacts

Pharmacosmos A/S Clinical and Non-clinical Research
study director · Pharmacosmos A/S

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion